Oppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform Rating
Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of Vanda Pharmaceuticals (NASDAQGM:VNDA) (DB:VM4) with a Outperform recommendation.
Prior to this coverage initiation, the stock closed at $5.21 on September 22, 2026. This latest close represents a one-week price change of +4.41% compared to the baseline close of $4.99 on September 15, 2026. Over a one-month period, the stock experienced a price change of -1.33% from the baseline close of $5.28 on August 21, 2026.
The current consensus target mean for the company stood at $12.43 as of September 15, 2026, with a median target of $11.73. This mean target represents an implied change of +138.60%. The prior consensus target mean was also $12.43 as of August 30, 2026, showing a consensus target revision of 0.00%.
Vanda Pharmaceuticals last reported earnings on August 5, 2026. The company reported an actual EPS of -1.04, compared to the estimated EPS of -0.5993. The actual revenue for the period was $50,529,000.00, which differed from the estimated revenue of $63,163,500.00.
According to recommendation data as of September 1, 2026, the current recommendation total is 10. This total consists of 2 strong buy, 6 buy, 2 hold, 0 sell, and 0 strong sell recommendations, resulting in a positive percentage of 80.0%, a hold percentage of 20.0%, and a negative percentage of 0.0%. These figures are identical to the prior recommendation period on August 1, 2026, which also recorded 2 strong buy, 6 buy, 2 hold, 0 sell, and 0 strong sell recommendations.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 23, 2026 | Oppenheimer | Outperform | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.